FULC 250117 6.00C (FULC250117C6000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

FULC250117C6000

Watchlist

0.27
+0.06+28.57%

15min DelayClose Jan 2 16:00 ET

0.29High0.20Low

Intraday

5D
Daily

News

Fulcrum Therapeutics Faces Genzyme Agreement Termination
TipRanksDec 23, 2024 16:57 ET
Express News | Fulcrum Therapeutics Inc - Sanofi to Terminate Collaboration and License Agreement With Fulcrum
ReutersDec 23, 2024 16:33 ET
Fulcrum Therapeutics Rumor Highlighted in Betaville Alert
TipRanksDec 23, 2024 13:55 ET
Express News | Shares Of Fulcrum Therapeutics See Volume; Traders Circulating Co. Mentioned By M&A Blog
BenzingaDec 23, 2024 13:50 ET
Fulcrum Therapeutics (NASDAQ:FULC) Shareholders Have Endured a 77% Loss From Investing in the Stock Three Years Ago
Yahoo FinanceDec 19, 2024 12:07 ET
Subdued Growth No Barrier To Fulcrum Therapeutics, Inc. (NASDAQ:FULC) With Shares Advancing 32%
Simply Wall StDec 15, 2024 07:23 ET

Comments

DCCTrader

Sep 26, 2024 19:48

$Fulcrum Therapeutics (FULC.US)$ 👀lot of meat on forcast but pattern is behaving like walking drunk man….

Jaguar8

Sep 12, 2024 07:11

NEWS

$Fulcrum Therapeutics (FULC.US)$
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Fulcrum Therapeutics (NASDAQ: FULC) announced that its Phase 3 REACH trial for losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) failed to meet its primary endpoint. The trial showed no significant improvement in relative surface area (RSA) compared to placebo at week 48. Secondary endpoints also failed to ...

Trytosaveabit

Jul 31, 2024 12:53

Up is the way!

$Fulcrum Therapeutics (FULC.US)$ Low volume indeed! But low or high volume, all that matters is that it’s moving up nicely

Trytosaveabit

Jul 31, 2024 06:11

Talk about a under estimated or a killer unexpected operating income! Hehehe!

$Fulcrum Therapeutics (FULC.US)$ Fulcrum Therapeutics Q2 Operating Income USD 52.492 Million Vs. IBES Estimate USD 361.4 Thousand! Hope the rest of the earnings looks like this? hehehe

Trytosaveabit

May 23, 2024 08:23

Note the timeline

$Fulcrum Therapeutics (FULC.US)$ Its lead candidate, Losmapimod, is a selective p38α/β mitogen-activated protein kinase inhibitor. It is a potentially transformative treatment for FSHD, a rare and debilitating disease for which no approved treatments exist. The FDA has since granted Losmapimod Fast Track designation and Orphan Drug Designation for treating this condition. It is undergoing a Phase 3 study, and Fulcrum expects to report topline data in the fourth quarter of 2024.